MAIA Biotechnology, Inc.
MAIA
$-0.07
Change (1 day)
$5.99
Year High
$0.82
Year Low
Categories
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Revenue of MAIA Biotechnology, Inc. (MAIA)
Revenue in 2023 (TTM): $
According to MAIA Biotechnology, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MAIA Biotechnology, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-20,182,381 | $-19,772,905 | $-19,772,905 |
| 2022 | $ | $ | $-16,176,200 | $-15,769,279 | $-15,805,968 |
| 2021 | $ | $ | $ | $-12,578,211 | $-13,285,741 |
| 2020 | $ | $ | $ | $-6,959,248 | $-6,668,207 |
| 2019 | $ | $ | $242 | $-6,921,114 | $-6,492,782 |